Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TG4010

National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antineoplastic AgentsCancer VaccinesMVA-MUC1-IL2 VaccineMembrane Glycoproteins

Narrower (1)

MVA-MUC1-IL2™

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
BackgroundAdvanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and… Expand
Highly Cited
2016
Highly Cited
2016
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
BACKGROUND MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a… Expand
  • figure 1
  • table 2
  • table 3
  • figure 3
  • table 4
Review
2014
Review
2014
Immunotherapy and lung cancer: current developments and novel targeted therapies.
Non-small-cell lung cancer (NSCLC) is a highly prevalent and aggressive disease. In the metastatic setting, major advances… Expand
  • figure 1
  • figure 2
2012
2012
TG4010: A therapeutic vaccine against MUC1 expressing tumors.
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as… Expand
Highly Cited
2011
Highly Cited
2011
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
BACKGROUND Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted… Expand
Highly Cited
2010
Highly Cited
2010
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the… Expand
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Highly Cited
2008
Highly Cited
2008
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
Background: TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This… Expand
Highly Cited
2008
Highly Cited
2008
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
SummaryPurpose: TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
2008
2008
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
8023 Background: TG4010 is a recombinant Modified Virus Ankara (MVA) expressing both IL2 and the tumor-associated antigen MUC1… Expand
Highly Cited
2003
Highly Cited
2003
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer
The MUC1 protein is a highly glycosylated mucin normally found at the apical surface of mucin‐secreting epithelial cells in many… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE